Acapella versus usual airway clearance during acute exacerbation in bronchiectasis: a randomized crossover trial

Size: px
Start display at page:

Download "Acapella versus usual airway clearance during acute exacerbation in bronchiectasis: a randomized crossover trial"

Transcription

1 Chronic Respiratory Disease 2007; 4: ORIGINAL PAPER Acapella versus usual airway clearance during acute exacerbation in bronchiectasis: a randomized crossover trial JE Patterson, O Hewitt, L Kent, I Bradbury, JS Elborn and JM Bradley Regional Respiratory Centre, Belfast City Hospital, Belfast, Northern Ireland Devices such as the Acapella may facilitate independent airway clearance, however, few clinical trials have investigated the efficacy of Acapella. The aim of this study was to compare the effectiveness of Acapella to usual airway clearance in adults during an acute exacerbation of bronchiectasis requiring oral antibiotic therapy. Twenty patients with bronchiectasis and an acute exacerbation requiring oral antibiotic therapy were recruited into a randomized crossover trial. Patients were allocated to one of two groups determined by concealed computer generated randomization. Group 1 (n 10): airway clearance session using Acapella at home twice daily during oral antibiotic therapy. Group 2 (n 10): usual airway clearance sessions at home during oral antibiotic therapy. Patients recorded duration of each treatment session, volume of sputum produced and perception of breathlessness. An independent assessor performed outcome measures of spirometric lung function, pulse oximetry and breathlessness at the beginning and end of the study period. The mean volume of sputum expectorated during Acapella sessions was greater than for usual airway clearance sessions although this difference was not significant 2.61 ml (95% CI-1.62 to 6.84). Mean duration of Acapella sessions was greater than usual airway clearance sessions and approached significance. There were no significant between group differences in changes in lung function. This study demonstrates that the Acapella device may offer an acceptable, user-friendly method of airway clearance in patients with bronchiectasis. Chronic Respiratory Disease 2007; 4: Key words: Acapella ; airway clearance techniques; bronchiectasis Introduction Respiratory exacerbations are characterized by increased cough and increased sputum production with changes in viscosity making expectoration difficult. 1, 2 Daily airway clearance to remove secretions is important in the management of bronchiectasis and during exacerbations more intensive airway clearance may be required. Moderate and severe exacerbations are treated with intravenous (IV) antibiotics often in an inpatient setting and with an intensive care package typically including one to two daily supervised airway clearance sessions. 1 Mild exacerbations are treated at home with a day course of oral antibiotics. 1 Adherence to airway clearance during an exacerbation is important in order to clear the increased sputum load. Correspondence: Judy M Bradley, Reader in Physiotherapy, Health and Rehabilitation Sciences Research Institute, School of Health Sciences, University of Ulster, Northern Ireland; and Regional Respiratory Centre, Belfast City Hospital, Lisburn Road, Belfast, BT9 7AB, Northern Ireland. jm.bradley@ulster.ac.uk It has been proposed that adherence with selfmanaged therapy is generally improved with userfriendly devices. 1 A recent UK survey showed that the active cycle of breathing techniques (ACBT) is the most frequently used airway clearance technique (ACT) in patients with bronchiectasis. 3 However, a number of devices (eg, positive expiratory pressure, Flutter, Acapella ) have also been used in the management of these patients. 3 6 Evidence of the effectiveness of ACTs in patients with bronchiectasis is limited and focuses on five randomized controlled trials (RCTs), only three of which exclusively involve patients with bronchiectasis. A long-term RCT showed the Flutter (Scandipharm, Birmingham, Alabama) device to be as effective as ACBT in 17 patients with bronchiectasis; a single intervention randomized crossover trial showed ACBT to be more effective than an inspiratory muscle training technique device in 20 patients with bronchiectasis; and a single intervention randomized crossover trial showed the Acapella (Smiths Medical, formerly DHD Healthcare, Wampsville, New York, CE approved) 2007 SAGE Publications /

2 68 device to be as effective as ACBT in 20 patients with bronchiectasis. 4,5,7 No previous studies have investigated airway clearance during exacerbations. The Acapella is a small hand-held device, which combines PEP and high-frequency oscillation therapy. The manufacturers suggest that Acapella may offer a beneficial alternative to other ACTs as it requires less therapist time, is self performed, can be used in any postural drainage position and is suitable to patients with a wide range of pulmonary function. No clinical trials have investigated the efficacy of Acapella during a pulmonary exacerbation requiring oral antibiotic therapy. The aim of this study was to compare the efficacy of Acapella with usual airway clearance in adults during an acute exacerbation of bronchiectasis requiring oral antibiotics. Methods The local ethics committee approved the study and written informed consent was obtained from all participants. Study design Patients were allocated to one of two groups determined by computer generated randomization performed by a clinician not involved in the trial. Codes for randomization were held in sealed envelopes and were unopened until the patient agreed to participate in the study. Group 1 (n 10) were required to perform airway clearance at home twice daily during oral antibiotic therapy using the Acapella device. Group 2 (n 10) were required to perform their usual airway clearance sessions at home during oral antibiotic therapy. Outcome measures were performed pre and post airway clearance session on day one and end day antibiotics (days 10 14) by an independent assessor (OH) blinded to group allocation. All patients were provided with a patient diary, 28 sputum containers (two for each day) calibrated with a scale measuring 0 20 ml and a Borg scale for perception of breathlessness. Methods Twenty adult patients with bronchiectasis (diagnosis by CT scan) were recruited from a specialist respiratory clinic at the Belfast City Hospital, Northern Ireland between January and August No suitable data was available to carry out a sample size calculation. Patients were studied during an acute exacerbation. As there are no criteria available to define an acute exacerbation in patients with bronchiectasis criteria developed in CF were used. An acute exacerbation was defined as the presence of four out of 12 symptoms of a respiratory exacerbation, and requiring a course of oral antibiotics. 8 Antibiotics were prescribed by a physician with expertise in bronchiectasis. Nineteen patients reported an increase in sputum volume or a change in sputum colour prior to inclusion in the trial. Exclusion criterions were: complications that would affect their ability to perform airway clearance such as pulmonary embolisms or haemoptysis; pulmonary infection requiring IV antibiotics; or inpatient admission. Both groups received a 30-minute training/assessment session on day one of their course of antibiotics with a physiotherapist (JP). The Group 1 patients training/assessment session included: determination of two postural drainage positions by auscultation; selection of the correct Acapella device (green Acapella for patients able to sustain an expiratory flow of greater than 15 L/M for at least three seconds and blue Acapella for patients with an expiratory flow of less than 15 L/M); determination of the correct Acapella settings; training on its use; and instruction to use the device for a maximum of 15 minutes in each postural drainage position or until patient could no longer tolerate treatment. The Group 2 patients training/ assessment involved review of their usual airway clearance regimen including: technique used, positioning, duration and frequency of treatments. Acapella Acapella consists of a counterweighted plug and metal strip attached to a lever, and a magnet. Airflow oscillations are created by the breaking and reforming of a magnetic attraction by the plug as it intermittently occludes air passing through the device. The device incorporates an adjustable frequency/resistance dial which adjusts the proximity of the magnet to the metal strip, thereby adjusting expiratory pressure, and amplitude and frequency of oscillations. The initial training session and subsequent treatment sessions were conducted as recommended by the manufacturer s of Acapella. During the initial training session patients were taught to exhale through the device (with the frequency/resistance dial set at minimum setting) in a three to four-second timeframe. If exhalation was too slow or too fast patients were encouraged to exhale more or less forcefully. A manometer was then included in the circuit and the frequency/resistance dial increased until the expiratory pressure reading was maintained between 10 and 20 cmh 2 O. Acapella was performed in the two predetermined postural drainage Chronic Respiratory Disease

3 69 positions. The components of the Acapella treatment included: breathing control, 10 breaths through the Acapella device inhaling to three-quarter maximum breathing capacity, two to three-second breath hold, active exhalation to function residual capacity (FRC), and cough or forced expiration (huff) in a set cycle. Usual airway clearance Usual was defined as the ACT currently used by the patient. In some patients usual airway clearance may potentially have been no airway clearance. A number of outcome measures were recorded in this study however sputum volume/weight were chosen to be the primary outcome. Patients were instructed to keep a record of duration of all treatment sessions, volume of sputum produced during treatment sessions and perception of breathlessness and to administer their medication (short-acting bronchodilaters, long-acting bronchodilaters and steroids, where applicable) at least one-hour pretreatment. Patients were contacted once per week and encouraged to comply with their airway clearance regimen and complete the diary. Outcome measures performed pre- and post airway clearance session on day one and end day antibiotics included: spirometric measures of lung function (Micro Lab, 3500 UK); pulse oximetry (Nellcor Puritan Bennett NPB 40); Borg breathlessness score; and 15-count breathlessness score. 9 The independent assessor also administered a short interview based symptoms questionnaire prior to airway clearance on day one and end day antibiotics (days 10 14) addressing patient perceived changes during the previous week in: sputum volume and colour, cough, exercise tolerance, dysponea, fatigue, sinus discharge and appetite. Number of coughs was recorded during airway clearance sessions on day one and final day antibiotics by a physiotherapist (JP). Assessments were conducted at approximately the same time on both days. At end day antibiotics the randomization code was broken after completion of all other outcome measures. This facilitated the independent assessor to administer a short questionnaire to all patients in Group 1 (Acapella group) determining preference of Acapella with their previous technique (Appendix 1). A further questionnaire was administered to these patients one month following completion of study to determine continued use of Acapella (Appendix 1). Analysis Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS version 11.0). The t-test for independent samples was used to compare sputum volumes and duration of treatment sessions. The t-test for paired samples was used to compare pre- and posttreatment outcome measures within each group. Analysis of covariance was used to compare between group pretreatment day 1 and pretreatment end antibiotic day lung function; between group day 1 and end antibiotic day cough counts and between group day 1 and end antibiotic day sputum volume. The Mann Whitney test was used to compare mean rank day 1 and end antibiotic day symptoms questionnaire. A P-value of 0.05 was considered statistically significant. Results All 20 patients completed the study (Figure 1). Demographic details as well as information on infecting organisms and antibiotics received are outlined in Table 1. There was no difference in baseline age or lung function between the groups. Two patients in Group 1 and one patient in Group 2 received a 10-day course of antibiotics, the remaining patients received a 14-day course of antibiotics. Oral antibiotics were prescribed according to sputum sensitivity results at their previous visit to the clinic and the likely current infecting organisms. Antibiotics were not changed in any patients during the course of the study. Of the seven patients who cultured organisms in their baseline sputum, the infecting organism (Haemophilis influenzae) was eradicated in four patients (Table 1). In one patient Pseudomonas aeruginosa was not eradicated; in one patient infected at baseline with Streptoccocus pneumoniae and H. influenzae only the S. pneumoniae was eradicated; and in one patient although the baseline infecting organisms (S. pneumoniae and H. influenzae) were eradicated P. aeruginosa was isolated at the end of antibiotics. Usual airway clearance regimens conducted by patients prior to the study included ACBT (n 14), autogenic drainage (n 2), PEP (n 2), Flutter (n 1) and no airway clearance (n 1) and usual mean daily duration of airway clearance was [mean (SD)] (16.30) minutes. Usual airway clearance regimens conducted by patients in Group 2 were: ACBT (n 9) and PEP (n 1). All patients in Group 1 and eight patients in Group 2 performed two airway clearance sessions per day (morning and evening); two patients in Group 2 performed one airway clearance session per day (morning). The mean volume of sputum expectorated during Acapella sessions was greater than for usual airway clearance sessions although this difference was not significant 2.61 ml (95% CI-1.62 to 6.84) (Table 2). There were no significant between group differences in

4 70 Figure 1 Flow diagram of the progress of patients through trial. Table 1 Demographic details: information of infecting organisms and antibiotics received Gender 10 M: 10 F FEV 1 % predicted Mean (SD) FEV (21.13) Age (years) Mean (SD) 61.1 (10.9) Infecting organisms Pseudomonas aeruginosa n 1 Haemophilis influenzae n 6 Commensals only n 13 Streptoccocus pneumoniae n 2 Antibiotics Ciprofloxacin n 14 Co Amoxiclav n 4 Doxycycline n 1 Co-trimoxazole n 1 Table 2 Between group differences in mean session volume of sputum expectorated and mean session duration Mean Acapella Usual Rx difference Rx Mean (SD) Mean (SD) (95% CI) P-value Sputum ml 0.31 volume (4.96) (3.99) (95% CI-1.62 (Rx sessions) to 6.84) (ml) Duration (Rx sessions) (2.73) (5.58) ( 0.22 to 8.26) (minutes) day one and final day (days 10 14) sputum volume [mean difference 1.16 ml (95% CI 2.36 to 0.04)]. The mean daily volume of sputum expectorated fluctuated over the period of antibiotic therapy although a greater amount of sputum was expectorated during Acapell. The mean duration of Acapella sessions was greater than of usual airway clearance sessions and approached significance [mean difference 4.02 minutes (95% CI 0.22 to 8.26) P 0.06] (Table 2). No significant differences were found between preand posttreatment lung function, SpO 2 or breathlessness for either group at day one or final day of antibiotics (days 10 14) indicating neither Acapella nor usual airway clearance increased airway obstruction or desaturation. There were no significant between group differences in change in pretreatment day one and pretreatment final day lung function: VC [mean difference 0.02 L (95% CI 0.21 to 0.17)], FVC [mean difference 0.16 L (95% CI 0.36 to 0.05)], FEV 1 [mean difference 0.09 L (95% CI 0.22 to 0.03)], PEF [mean difference L/min (95% CI to 79.64)] (Table 3). There were no significant between group differences in day one and final day cough counts. There were no significant between group differences in patient perception of changes in: sputum volume or colour; cough; exercise tolerance; dyspnoea; or fatigue between beginning and end of study period. Patient Chronic Respiratory Disease

5 71 Figure 2 Mean daily sputum volumes. Table 3 Between group differences in changes in pretreatment day one and pretreatment final day lung function perception of changes in sinus discharge and appetite between beginning and end of study period were improved in the Acapella group and approached significance (Table 4). No patients in either group reported any side effects from their airway clearance treatment. Seven patients in group one preferred Acapella to their usual airway clearance used previous to the study, one patient had no preference and two patients preferred their usual airway clearance. One month post study, seven patients were using Acapella every day, two patients were using Acapella three to four times a week and one patient was not using Acapella at all. Discussion Mean difference (95% CI) P-value FEV 1 (L) ( 0.22 to 0.03) FVC (L) ( 0.36 to 0.05) VC (L) to 0.07) PEF (L/min) ( to 79.64) This study demonstrates that the Acapella device offers an alternative acceptable method of clearance Table 4 Between group differences in changes in day one and final day respiratory symptoms Acapella Rx Mean Usual Rx Significance rank Mean rank of mean difference difference difference Sputum volume Sputum colour Intensity of cough Frequency of cough Exercise tolerance Fatigue Sinus discharge Appetite to usual airway clearance in patients with bronchiectasis and an acute exacerbation of their condition requiring treatment with oral antibiotics. The most common usual airway clearance techniques in this group of patients prior to the study were ACBT, autogenic drainage and PEP. This trial contributes to the limited evidence base for airway clearance in bronchiectasis: first, it investigates the efficacy of a new airway clearance device, Acapella, and second, it provides unique data regarding daily changes in sputum output during an oral antibiotic treatment in patients with bronchiectasis. The Acapella device creates PEP and oscillatory vibrations of the air within the airways by resisting and intermittently occluding expiratory air flow through the device. It has been proposed that PEP therapy creates a positive back pressure during expiration that splints open the peripheral airways, temporarily

6 72 increasing lung volume and allowing air to move behind the obstructed lung segments through collateral ventilation pathways. 10, 11 The device generates oscillations of between zero and 30 Hertz during expiration, which further facilitates the mobilization of secretions. Expiratory flow moves secretions into the central airways where they are expectorated following cough or huff. A clinical short-term study compared Acapella with ACBT in patients with stable bronchiectasis and showed the techniques to be equally as effective. 5 A laboratory study compared Acapella with an established oscillatory PEP device, the Flutter. 12 The devices were compared in terms of PEP, oscillatory pressure amplitude and frequency over a clinically relevant range of flows produced from a compressed oxygen source. The study demonstrated that Acapella had similar performance characteristics to the Flutter but produced more stable air flow oscillations at the highest and lowest flow settings tested. 12 Acapella may therefore be suitable for patients with a wider range of lung function and can also be used in any postural drainage position. No previous studies have investigated airway clearance in patients with an acute exacerbation of bronchiectasis. In this study there were no between group differences in any parameters of lung function. This is usual in mild exacerbations such as these. In a study of severe exacerbations treated with intravenous antibiotics only small non-significant improvements in FEV 1 was described. 13 Lung function has been traditionally used as the primary outcome measure in airway clearance studies. This is based on the assumption that retention of sputum reduces airway diameter and contributes to airflow obstruction. However, Van der Schans postulates that although measurement of lung function is important in airway clearance studies to evaluate possible side effects, lung function is neither sensitive nor specific enough to detect clinically important changes in sputum transport. 14 The use of alternative outcome measures that relate closely to the overall objective of airway clearance, that is to improve muco-ciliary transport, may therefore be more relevant. For example, the use of inhaled radioactive aerosols may more accurately quantify changes in muco-ciliary transport. However, these cannot be performed easily and in general it has been shown that improvement in sputum transport as quantified by inhaled radioactive aerosols was associated with an improvement in sputum transport quantified by volume of expectorated sputum. 14 Sputum volume was recorded as the primary outcome measure in this trial for two reasons. Sputum volume provides information which establishes the short term clinical efficacy and safety of this new airway clearance adjunct. Only when short term efficacy and safety become established as in this trial, should the effect on relevant endpoint (or endpoints) be investigated. Furthermore, despite controversy surrounding the use of outcome measures relating to sputum load, amount of sputum expectorated is an outcome measure of key importance to patients. In this trial sputum volume was used in preference to sputum weight as patients were involved in the trial concurrently and therefore it was not feasible to provide individual patients with weighing scales. Previous studies have suggested that sputum volume and weight are comparable and that each gram of sputum is considered to have a volume equivalent to 1 ml. 15 Van der Schans highlights that an important but often overlooked aspect of sputum expectoration is the subjective experience of the patient. This is important as one of the potential effects of airway clearance is to make sputum clearance more efficient for the patient. 14 This study shows that patients perceived changes in sputum volume and other symptoms related to the potential effects of airway clearance improve irrespective of group allocation, and the between group differences do not reach significance. In this study the main daily sputum volume expectorated using Acapella showed an overall decrease from day one through to day 14 with the greatest percentage decrease from baseline at final day antibiotics. The daily sputum volume expectorated using usual airway clearance fluctuated throughout the antibiotic period with the mean percentage change from baseline almost zero at final day antibiotics. A limitation of this study was the reliance on patient self-reported outcome measures. However, every effort was taken to minimize errors, for example, calibrated containers were provided to measure sputum and patients were contacted weekly to encourage adherence and the completion of the patient diary which were completed daily by all patients in the study. In summary sputum clearance was greater in the group of patients in this study who incorporated the Acapella device into their regimen spending a greater period of time performing airway clearance. Many patients prefer to use user-friendly devices to facilitate airway clearance and follow-up evaluation suggested the Acapella device may facilitate long term adherence to regular airway clearance. This study demonstrates the Acapella device may offer a user-friendly alternative to usual methods of airway clearance. Chronic Respiratory Disease

7 References 1. Silverman E, Ebright L, Kwiatkowski M, Cullina J. Current management of bronchiectasis: review and 3 case studies. Lung 2003; 32: Evans DJ, Greenstone M. Long-term antibiotics in the management of non-cf bronchiectasis do they improve outcome? Respir Med 2003; 97: O Neill B, Bradley JM, McCardle N, MacMahon J. The current physiotherapy management of patients with bronchiectasis: a UK survey. Int J Clin Pract 2002; 56: Thompson CS, Harrison S, Ashley J, Day K, Smith DL. Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax 2002; 57: Patterson JE, Bradley JM, Hewitt O, Bradbury I, Elborn JS. Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques (ACBT) versus Acapella. Respiration 2005; 72: Pryor JA. Physical therapy for adults with bronchiectasis. Clin Pulm Med 2004; 11: Patterson JE, Bradley JM, Elborn JS. : a randomized crossover trial of active cycle of breathing techniques (incorporating postural drainage and vibration) versus test of incremental respiratory endurance. Chron Respir Dis 2004; 1: Ramsey BW, Pepe M, Williams WJ. Pulmonary exacerbation (PE): How do we define it? Pediatr Pulmonol 1994; 9 (Suppl): Prasad SA, Randall SD, Balfour-Lynn IM. Fifteen-count breathlessness score: an objective measure for children. Pediatr Pulmonol 2000; 30: Falk M, Andersen JB. Positive expiratory presseure (PEP) mask. In Pryor JA ed. Respiratory care. Churchill Livingstone, 1991: Falk M, Kelstrup M, Andersen JB, Kinoshita T, Falk P, Stovring S, Gothgen I. Improving the ketchup bottle method with positive expiratory pressure, PEP, in cystic fibrosis. Eur J Respir Dis 1984; 65: Volsko TA, DiFore JM, Chatburn RL. Performance comparison of two oscillating positive expiratory pressure devices: Acapella versus Flutter. Respir Care 2003; 48: Watt AP, Brown V, Courtney J et al. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 59: Van der Schans CP, Postma DS, Koeter GH, Rubin BK. Physiotherapy and bronchial mucus transport. Euro Respir J 1999; 13: Wilson MJB, Martin DE. Quantitative sputum culture as a means of excluding false positive reports in the routine microbiology laboratory. J Clin Path 1972; 25: Appendix 1 Preference questionnaire Part 1 Which of the following treatment techniques would you prefer: Acapella to your normal airway clearance regimen which you used prior to this study Go to part 2 your normal airway clearance regimen to Acapella Go to part 3 no preference Go to part 4 Part 2 Can you think of any reasons why you preferred Acapella to your normal airway clearance regimen, which you used prior to this study? I will now read a list of reasons, which some people who have used Acapella, have given as to why they have preferred this method of airway clearance. I will pause after each item long enough for you to tell me if you agree, disagree or don t know. The reasons are: Increased sputum expectoration with Acapella Shorter treatment time with Acapella Less effort required during airway clearance with Acapella Decreased feeling of breathlessness with Acapella Part 3 Can you think of any reasons why you preferred your normal airway clearance regimen, which you used prior to this study to Acapella? I will now read a list of reasons, which some people who have used Acapella, have given as to why they have preferred their normal airway clearance regimen. I will pause after each item long enough for you to tell me if you agree, disagree or don t know. The reasons are: Increased sputum expectoration with your normal airway clearance regime Shorter treatment time with your normal airway clearance regime Less effort required during airway clearance with your normal airway clearance regimen Decreased feeling of breathlessness with your normal airway clearance regimen 73

8 74 Part 4 Can you think of any reasons why you had no preference between your normal airway clearance regimen, which you used prior to this study to Acapella? I will now read a list of reasons, which some people who have used Acapella, have given as to why they had no preference between Acapella and their normal airway clearance regimen. I will pause after each item long enough for you to tell me if you agree, disagree or don t know. The reasons are: Similar sputum expectoration with both Acapella and your normal airway clearance regimen Similar treatment time with both Acapella and your normal airway clearance regimen Similar effort required during both Acapella and your normal airway clearance regimen Similar feelings of breathlessness with Acapella and your normal airway clearance regimen One-month post study questionnaire Telephone interview 1. How often have you used Acapella since completing the trial? (a) every day (b) three to four times a week (c) once a week (d) not at all 2. How often have you used your normal airway clearance since completing the trial? (a) every day (b) three to four times a week (c) once a week (d) not at all Chronic Respiratory Disease

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Autogenic Drainage versus Acapella for Airway Clearance in Patients with Bronchiectasis: Randomized

More information

The Use of Active Cycle of Breathing Technique (ACBT) In Pulmonary Physiotherapy: A Critical Review of the Literature Lauro G. Villegas Jr.

The Use of Active Cycle of Breathing Technique (ACBT) In Pulmonary Physiotherapy: A Critical Review of the Literature Lauro G. Villegas Jr. The Use of Active Cycle of Breathing Technique (ACBT) In Pulmonary Physiotherapy: A Critical Review of the Literature Lauro G. Villegas Jr., PTRP Keywords: Active Cycle of Breathing Technique (ACBT), Pulmonary

More information

acapella vibratory PEP Therapy System Maximizing Therapy Effectiveness, Empowering Patient Compliance

acapella vibratory PEP Therapy System Maximizing Therapy Effectiveness, Empowering Patient Compliance acapella vibratory PEP Therapy System Maximizing Therapy Effectiveness, Empowering Patient Compliance Investigating Questions Each acapella vibratory PEP therapy system uniquely provides PEP therapy by

More information

Bronchial Hygiene Therapy

Bronchial Hygiene Therapy WHITE PAPER Bronchial Hygiene Therapy OBJECTIVES At the conclusion of this paper the reader should have an understanding of the following: A background of chest physiotherapy, and rational for use of Positive

More information

Section: Durable Medical Equipment Last Reviewed Date: June Policy No: 45 Effective Date: September 1, 2014

Section: Durable Medical Equipment Last Reviewed Date: June Policy No: 45 Effective Date: September 1, 2014 Medical Policy Manual Topic: Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Disorders Date of Origin: May 26, 2011 Section: Durable Medical Equipment Last Reviewed Date:

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Oscillatory Devices for the Treatment of Respiratory Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: oscillatory_devices_for_treatment_of_respiratory_conditions

More information

High Frequency Chest Wall Oscillation Devices

High Frequency Chest Wall Oscillation Devices High Frequency Chest Wall Oscillation Devices Policy Number: Original Effective Date: MM.01.007 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 10/24/2014 Section: DME

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: None Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Description Oscillatory devices are alternatives to

More information

Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing

Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing Doug Pursley, MEd, RRT-ACCS, FAARC Introduction Previous studies reporting performance characteristics of Oscillating

More information

Positive Expiratory pressure (PEP), Acapella and Flutter

Positive Expiratory pressure (PEP), Acapella and Flutter Positive Expiratory pressure (PEP), Acapella and Flutter Full Title of Guideline: Author (include email and role): Division & Speciality: Version: 3 Ratified by: Scope (Target audience, state if Trust

More information

CYSTIC FIBROSIS INPATIENT PROTOCOL PURPOSE POLICY STATEMENTS SITE APPLICABILITY PRACTICE LEVEL/COMPETENCIES DEFINITIONS EQUIPMENT

CYSTIC FIBROSIS INPATIENT PROTOCOL PURPOSE POLICY STATEMENTS SITE APPLICABILITY PRACTICE LEVEL/COMPETENCIES DEFINITIONS EQUIPMENT PURPOSE Physiotherapy role for inpatients with cystic fibrosis. POLICY STATEMENTS On admission to hospital all patients will be assessed by the physiotherapist within 24 hours. Physiotherapists have standing

More information

Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review)

Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review) Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review) Elkins MR, Jones A, van der Schans C This is a reprint of a Cochrane review, prepared and maintained

More information

Bronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago

Bronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago Bronchiectasis Grant Waterer MBBS PhD MBA FRACP FCCP Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago Conflicts of Interest I have

More information

Evaluation of Functional Characteristics of 4 Oscillatory Positive Pressure Devices in a Simulated Cystic Fibrosis Model

Evaluation of Functional Characteristics of 4 Oscillatory Positive Pressure Devices in a Simulated Cystic Fibrosis Model Evaluation of Functional Characteristics of 4 Oscillatory Positive Pressure Devices in a Simulated Cystic Fibrosis Model Hillary Van Fleet MSc RRT, Diane K Dunn RRT-NPS, Neil L McNinch MSc RN, and Teresa

More information

Gil Sokol, Daphna Vilozni PhD, Ran Hakimi, Moran Lavie MD, Ifat Sarouk MD, Bat-El Bar MD, Adi Dagan MD, Miryam Ofek MD, and Ori Efrati MD

Gil Sokol, Daphna Vilozni PhD, Ran Hakimi, Moran Lavie MD, Ifat Sarouk MD, Bat-El Bar MD, Adi Dagan MD, Miryam Ofek MD, and Ori Efrati MD The Short-Term Effect of Breathing Tasks Via an Incentive Spirometer on Lung Function Compared With Autogenic Drainage in Subjects With Cystic Fibrosis Gil Sokol, Daphna Vilozni PhD, Ran Hakimi, Moran

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association of Cystic Fibrosis and Other Respiratory Disorders Page 1 of 23 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oscillatory Devices for the Treatment of Cystic Fibrosis

More information

Active Cycle of Breathing Technique

Active Cycle of Breathing Technique Active Cycle of Breathing Technique Full Title of Guideline: Author (include email and role): Division & Speciality: Version: 3 Ratified by: Scope (Target audience, state if Trust wide): Review date (when

More information

4.6 Small airways disease

4.6 Small airways disease 4.6 Small airways disease Author: Jean-Marc Fellrath 1. INTRODUCTION Small airways are defined as any non alveolated and noncartilaginous airway that has an internal diameter of 2 mm. Several observations

More information

Protocol. Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions

Protocol. Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions Oscillatory Devices for the Treatment of Cystic Fibrosis and Other (10115) Medical Benefit Effective Date: 01/01/18 Next Review Date: 07/18 Preauthorization No Review Dates: 01/07, 03/08, 03/09, 03/10,

More information

A Place For Airway Clearance Therapy In Today s Healthcare Environment

A Place For Airway Clearance Therapy In Today s Healthcare Environment A Place For Airway Clearance Therapy In Today s Healthcare Environment Michigan Society for Respiratory Care 2015 Fall Conference K. James Ehlen, MD October 6, 2015 Objectives Describe patients who will

More information

Original Article. Hospital, Mahidol University 3) Division of Respiratory Disease and Tuberculosis, Department of Medicine, Faculty of

Original Article. Hospital, Mahidol University 3) Division of Respiratory Disease and Tuberculosis, Department of Medicine, Faculty of Original Article Efficacy of Pursed Lips Breathing with Forced Expiration Techniques and Active Cycle of Breathing Technique on Pulmonary Mucus Clearance in Healthy Subjects J. Phys. Ther. Sci. 22: 247

More information

Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions

Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions Policy Number: 1.01.15 Last Review: 3/2018 Origination: 3/2001 Next Review: 3/2019 Policy Blue Cross and Blue Shield

More information

Physiotherapy in lung disease - top tips for clinicians. Sita Kansagra Specialist Outpatient Physiotherapist

Physiotherapy in lung disease - top tips for clinicians. Sita Kansagra Specialist Outpatient Physiotherapist Physiotherapy in lung disease - top tips for clinicians Sita Kansagra Specialist Outpatient Physiotherapist Aims: Run through current physiotherapy practice Airway clearance Pulmonary rehabilitation Dysfunctional

More information

Bronchiectasis. Introduction. Key points

Bronchiectasis. Introduction. Key points 15 Bronchiectasis Introduction i Key points Patients with bronchiectasis typically have chronic airway infection, punctuated by acute exacerbations and accompanied by progressive airflow obstruction. Bronchiectasis

More information

The objectives of this presentation are to

The objectives of this presentation are to 1 The objectives of this presentation are to 1. Review the mechanics of airway clearance 2. Understand the difference between secretion mobilization and secretion clearance 3. Identify conditions that

More information

Small Volume Nebulizer Treatment (Hand-Held)

Small Volume Nebulizer Treatment (Hand-Held) Small Volume Aerosol Treatment Page 1 of 6 Purpose Policy Physician's Order Small Volume Nebulizer Treatment To standardize the delivery of inhalation aerosol drug therapy via small volume (hand-held)

More information

High Frequency Chest Wall Oscillation Devices

High Frequency Chest Wall Oscillation Devices High Frequency Chest Wall Oscillation Devices Policy Number: Original Effective Date: MM.01.007 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/18/2015 Section: DME

More information

REGISTER NO: ELECTIVE: PHYSIOTHERAPY IN CARDIO-RESPIRATORY

REGISTER NO: ELECTIVE: PHYSIOTHERAPY IN CARDIO-RESPIRATORY EFFECT OF ACTIVE CYCLE BREATHING TECHNIQUE ALONG WITH INCENTIVE SPIROMETRY VERSUS ACTIVE CYCLE BREATHING TECHNIQUE ALONG WITH ACAPELLA IN PATIENTS WITH MODERATE COPD REGISTER NO: 271530181 ELECTIVE: PHYSIOTHERAPY

More information

Positive expiratory pressure techniques in respiratory patients: old evidence and new insights

Positive expiratory pressure techniques in respiratory patients: old evidence and new insights The ERS designates this educational activity for a maximum of 1 CME credit. For information on how to earn CME credits, see page 81, or visit www.ers-education.org/ breathe-cme.htm Positive expiratory

More information

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Vallières, E., Tumelty, K., Tunney, M. M., Hannah, R., Hewitt, O., Elborn, J. S., & Downey, D. G. (2017). Efficacy of Pseudomonas

More information

Cystic Fibrosis Physiotherapy

Cystic Fibrosis Physiotherapy Cystic Fibrosis Physiotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission December

More information

Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions

Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions Medical Policy Manual Durable Medical Equipment, Policy No. 45 Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions Next Review: June 2019 Last Review: June 2018 Effective:

More information

Pressures and Oscillation Frequencies Generated by Bubble-Positive Expiratory Pressure Devices

Pressures and Oscillation Frequencies Generated by Bubble-Positive Expiratory Pressure Devices Pressures and Oscillation Frequencies Generated by Bubble-Positive Expiratory Pressure Devices Mary D Santos MSc PT, Maree A Milross PhD PT, John P Eisenhuth MSc, and Jennifer A Alison PhD PT BACKGROUND:

More information

Bronchiectasis. What is bronchiectasis? What causes bronchiectasis?

Bronchiectasis. What is bronchiectasis? What causes bronchiectasis? This factsheet explains what bronchiectasis is, what causes it, and how it is diagnosed and managed. More detailed information is available on the Bronchiectasis Patient Priorities website: www.europeanlunginfo.org/bronchiectasis

More information

Disclaimer. Objectives. I can t cough it up! Airway Clearance Therapy. Heather Murgatroyd, RRT, RPSGT Field Clinical Specialist

Disclaimer. Objectives. I can t cough it up! Airway Clearance Therapy. Heather Murgatroyd, RRT, RPSGT Field Clinical Specialist I can t cough it up! Airway Clearance Therapy Heather Murgatroyd, RRT, RPSGT Field Clinical Specialist 1 Disclaimer Name of presenter: Heather Murgatroyd, BA, RRT, RPSGT Name of employer: RespirTech I

More information

Norman Wolkove, MD, FCCP; Hany Kamel, MD; Michael Rotaple, MD; and Marc A. Baltzan Jr., MD

Norman Wolkove, MD, FCCP; Hany Kamel, MD; Michael Rotaple, MD; and Marc A. Baltzan Jr., MD Use of a Mucus Clearance Device Enhances the Bronchodilator Response in Patients With Stable COPD* Norman Wolkove, MD, FCCP; Hany Kamel, MD; Michael Rotaple, MD; and Marc A. Baltzan Jr., MD Study objective:

More information

Mai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012

Mai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012 Mai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012 Recognize the importance of Pulmonary Function Testing in Cystic Fibrosis Be aware of different types

More information

The Value of Exercise in the Cystic Fibrosis Clinic. Dr Patrick J Oades

The Value of Exercise in the Cystic Fibrosis Clinic. Dr Patrick J Oades The Value of Exercise in the Cystic Fibrosis Clinic Dr Patrick J Oades WHO Global recommendations for physical activity and health 2010. Geneva: WHO Library Cataloguing-in-Publication Data. [ISBN: 978

More information

Laboratory Evaluation of the Acapella Device: Pressure Characteristics Under Different Conditions, and a Software Tool to Optimize Its Practical Use

Laboratory Evaluation of the Acapella Device: Pressure Characteristics Under Different Conditions, and a Software Tool to Optimize Its Practical Use Laboratory Evaluation of the Acapella Device: Pressure Characteristics Under Different Conditions, and a Software Tool to Optimize Its Practical Use Carlos Eduardo Alves Silva PT MSc, Josiel G Santos Eng,

More information

Bronchiectasis is a chronic lung condition. Self-management in bronchiectasis: the patients perspective

Bronchiectasis is a chronic lung condition. Self-management in bronchiectasis: the patients perspective Eur Respir J 2007; 29: 541 547 DOI: 10.1183/09031936.00057306 CopyrightßERS Journals Ltd 2007 Self-management in bronchiectasis: the patients perspective K. Lavery*,#, B. O Neill #, J.S. Elborn*,", J.

More information

Published in: Archives of Physical Medicine and Rehabilitation

Published in: Archives of Physical Medicine and Rehabilitation A comparison of twice-versus once-weekly supervision during pulmonary rehabilitation in chronic obstructive pulmonary disease. O'Neill, B., McKevitt, A. M., Rafferty, S., Bradley, J. M., Johnston, D.,

More information

Respiratory Management- Your Questions Answered! Michelle Chatwin, PhD Consultant Physiotherapist

Respiratory Management- Your Questions Answered! Michelle Chatwin, PhD Consultant Physiotherapist Respiratory Management- Your Questions Answered! Michelle Chatwin, PhD Consultant Physiotherapist Why Are People Affected Differently Neuromuscular Disease; A Spectrum Its severity varies widely within

More information

Short-Term Effects of High-Frequency Chest Compression and Positive Expiratory Pressure in Patients With Cystic Fibrosis

Short-Term Effects of High-Frequency Chest Compression and Positive Expiratory Pressure in Patients With Cystic Fibrosis Elmer Original Article ress Short-Term Effects of High-Frequency Chest Compression and Positive Expiratory Pressure in Patients With Cystic Fibrosis Valentina Fainardi a, Francesco Longo a, Silvia Faverzani

More information

Northumbria Healthcare NHS Foundation Trust. Bronchiectasis. Issued by Respiratory Medicine

Northumbria Healthcare NHS Foundation Trust. Bronchiectasis. Issued by Respiratory Medicine Northumbria Healthcare NHS Foundation Trust Bronchiectasis Issued by Respiratory Medicine The aim of this booklet is to help you manage your bronchiectasis. It contains information which you should find

More information

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association MEDICAL POLICY SUBJECT: AIRWAY CLEARANCE DEVICES: OSCILLATORY DEVICES (e.g. High frequency MECHANICAL PERCUSSORS AND ASSISTED 04/15/04, 04/21/05, 02/16/05, PAGE: 1 OF: 8 If a product excludes coverage

More information

Physiotherapy treatment in cystic fibrosis: airway clearance techniques. Factsheet March Fighting for a

Physiotherapy treatment in cystic fibrosis: airway clearance techniques. Factsheet March Fighting for a Physiotherapy treatment in cystic fibrosis: airway clearance techniques Factsheet March 2013 Fighting for a Life Unlimited Physiotherapy treatment in cystic fibrosis: airway clearance techniques Introduction

More information

Terapias no farmacológicas de aclaramiento de la vía aérea y soporte respiratorio muscular en

Terapias no farmacológicas de aclaramiento de la vía aérea y soporte respiratorio muscular en Terapias no farmacológicas de aclaramiento de la vía aérea y soporte respiratorio muscular en el paciente ventilado: Estado del arte João Carlos Winck, MD, PhD Coordinator of the Respiratory Medicine Unit

More information

Overview of Cystic fibrosis in children. Apeksha Sathyaprasad, MD Pediatric pulmonologist

Overview of Cystic fibrosis in children. Apeksha Sathyaprasad, MD Pediatric pulmonologist Overview of Cystic fibrosis in children Apeksha Sathyaprasad, MD Pediatric pulmonologist No conflicts of interest OBJECTIVES Review pathophysiology of pulmonary disease in cystic fibrosis Review diagnostic

More information

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research  ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Comparison of Quake and RC-Cornet for Airway Clearance in Bronchiectasis: A Randomized Crossover

More information

CCLI. Bronchiectasis Treatment Antibiotics. Charles Haworth. Physician / Patient Conference, Georgetown University, May 2017

CCLI. Bronchiectasis Treatment Antibiotics. Charles Haworth. Physician / Patient Conference, Georgetown University, May 2017 Physician / Patient Conference, Georgetown University, May 2017 Bronchiectasis Treatment Antibiotics Charles Haworth CCLI Cambridge Centre for Lung Infection Disclosures Educational talks and / or consultancy

More information

Association of Chartered Physiotherapists in Cystic Fibrosis (ACPCF)

Association of Chartered Physiotherapists in Cystic Fibrosis (ACPCF) I N F O R M A T I O N STANDARDS OF CARE AND GOOD CLINICAL PRACTICE FOR THE PHYSIOTHERAPY MANAGEMENT OF CYSTIC FIBROSIS Association of Chartered Physiotherapists in Cystic Fibrosis (ACPCF) Second Edition

More information

Domiciliary Positive Expiratory Pressure Improves Pulmonary Function and Exercise Capacity in Patients with Chronic Obstructive Pulmonary Disease

Domiciliary Positive Expiratory Pressure Improves Pulmonary Function and Exercise Capacity in Patients with Chronic Obstructive Pulmonary Disease ORIGINAL ARTICLE Domiciliary Positive Expiratory Pressure Improves Pulmonary Function and Exercise Capacity in Patients with Chronic Obstructive Pulmonary Disease Chien-Ling Su, 1 Ling-Ling Chiang, 1 Ting-Yi

More information

Endobronchial valve insertion to reduce lung volume in emphysema

Endobronchial valve insertion to reduce lung volume in emphysema NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Endobronchial valve insertion to reduce lung volume in emphysema Emphysema is a chronic lung disease that

More information

greatly reduced [5]. However, bronchiectasis still accounts for 5% of hospital admissions relating to respiratory conditions in Hong Kong [6]. Airway

greatly reduced [5]. However, bronchiectasis still accounts for 5% of hospital admissions relating to respiratory conditions in Hong Kong [6]. Airway Research Report POSTURAL DRAINAGE OR FLUTTER DEVICE IN CONJUNCTION WITH BREATHING AND COUGHING COMPARED TO BREATHING AND COUGHING ALONE IN IMPROVING SECRETION REMOVAL AND LUNG FUNCTION IN PATIENTS WITH

More information

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh Bronchiectasis Domiciliary treatment Prof. Adam Hill Royal Infirmary and University of Edinburgh Plan of talk Background of bronchiectasis Who requires IV antibiotics Domiciliary treatment Results to date.

More information

Original Contributions

Original Contributions Original Contributions Performance Analysis of the Flutter VRP1 Under Different Flows and Angles Luiz Antonio Alves PT MSc, Fábio Pitta PT PhD, and Antonio Fernando Brunetto PT PhD BACKGROUND: The Flutter

More information

Populations Interventions Comparators Outcomes Individuals: With cystic fibrosis. therapy. therapy

Populations Interventions Comparators Outcomes Individuals: With cystic fibrosis. therapy. therapy Oscillatory Devices for the Treatment of Cystic Fibrosis and Other (10115) Medical Benefit Effective Date: 01/01/18 Next Review Date: 07/19 Preauthorization No Review Dates: 01/07, 03/08, 03/09, 03/10,

More information

National Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008

National Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008 Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not

More information

TITLE: Hypertonic Saline Nebules for Patients with Cystic Fibrosis and Bronchioectasis: A Review of the Clinical and Cost-Effectiveness

TITLE: Hypertonic Saline Nebules for Patients with Cystic Fibrosis and Bronchioectasis: A Review of the Clinical and Cost-Effectiveness TITLE: Hypertonic Saline Nebules for Patients with Cystic Fibrosis and Bronchioectasis: A Review of the Clinical and Cost-Effectiveness DATE: 16 March 2009 CONTEXT AND POLICY ISSUES: Hypertonic saline

More information

COPD Bronchiectasis Overlap Syndrome.

COPD Bronchiectasis Overlap Syndrome. COPD Bronchiectasis Overlap Syndrome. John R Hurst 1, J Stuart Elborn 2, and Anthony De Soyza 3 on Behalf of the BRONCH-UK Consortium (D Bilton, J Bradley, JS Brown, J Duckers, F Copeland, A Floto, J Foweraker,

More information

Respiratory Research Newsletter

Respiratory Research Newsletter Date Published: September 2012 Respiratory Research Newsletter Contents Research at the Belfast Trust 1 NICRN Respiratory Health 2 The Respiratory Research Team 3 Our Partners 4 Getting Involved in Upcoming

More information

Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600

Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600 Endobronchial valve insertion to reduce lung volume in emphysema Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600 Your responsibility This guidance represents

More information

Have you reached a tipping point in what you prescribe for airway clearance?

Have you reached a tipping point in what you prescribe for airway clearance? Have you reached a tipping point in what you prescribe for airway clearance? 500 Sixth Avenue NW, New Prague, MN 56071 Phone: 800.462.1045 or 952.758.9299 Fax: 866.758.5077 info@electromed.com www.smartvest.com

More information

Shared Care Guideline

Shared Care Guideline Shared Care Guideline Gentamicin for Nebulisation For the long term prophylaxis of chronic lung infections in non CF bronchiectasis Executive Summary Indication Nebulised gentamicin is indicated in patients

More information

MSRC AIR Course Karla Stoermer Grossman, MSA, BSN, RN, AE-C

MSRC AIR Course Karla Stoermer Grossman, MSA, BSN, RN, AE-C MSRC AIR Course Karla Stoermer Grossman, MSA, BSN, RN, AE-C Explain the importance of objective measures in the management of asthma Explain the different types of objective measures used in the management

More information

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1 58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family

More information

BTS Guideline for Home Oxygen use in adults Appendix 9 (online only) Key Questions - PICO 10 December 2012

BTS Guideline for Home Oxygen use in adults Appendix 9 (online only) Key Questions - PICO 10 December 2012 BTS Guideline for Home Oxygen use in adults Appendix 9 (online only) Key Questions - PICO 10 December 2012 Evidence base for Home Oxygen therapy in COPD, non-copd respiratory disease and nonrespiratory

More information

Changes in the management of children with Cystic Fibrosis. Caroline Murphy & Deirdre O Donovan CF Nurses

Changes in the management of children with Cystic Fibrosis. Caroline Murphy & Deirdre O Donovan CF Nurses Changes in the management of children with Cystic Fibrosis Caroline Murphy & Deirdre O Donovan CF Nurses What Is Cystic Fibrosis? Cystic fibrosis (CF) is an inherited chronic disease that primarily affects

More information

POSTURAL DRAINAGE. To safely and effectively teach and supervise a service user undertaking Postural Drainage as a means of airways clearance.

POSTURAL DRAINAGE. To safely and effectively teach and supervise a service user undertaking Postural Drainage as a means of airways clearance. POSTURAL DRAINAGE AIM To safely and effectively teach and supervise a service user undertaking Postural Drainage as a means of airways clearance. To assess users ability to complete independent treatments

More information

Standards of Care and Good Clinical Practice for the Physiotherapy Management of Cystic Fibrosis. Second edition. June 2011.

Standards of Care and Good Clinical Practice for the Physiotherapy Management of Cystic Fibrosis. Second edition. June 2011. Cystic Fibrosis Trust 11 London Road Bromley Kent BR1 1BY Tel: 020 8464 7211 Fax: 020 8313 0472 enquiries@cysticfibrosis.org.uk cysticfibrosis.org.uk Cystic Fibrosis Trust 2013. This factsheet may be copied

More information

The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis

The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis Respiratory Medicine (2012) 106, 661e667 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis

More information

Jennifer R Bishop, Odette J Erskine and Peter G Middleton

Jennifer R Bishop, Odette J Erskine and Peter G Middleton Timing of dornase alpha inhalation does not affect the efficacy of an airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial Jennifer R Bishop, Odette J Erskine and Peter

More information

NON-CF BRONCHIECTASIS IN ADULTS

NON-CF BRONCHIECTASIS IN ADULTS Séminaire de Pathologie Infectieuse Jeudi 25 juin 2008 Cliniques Universitaires UCL de Mont-Godinne, Yvoir NON-CF BRONCHIECTASIS IN ADULTS Dr Robert Wilson Royal Brompton Hospital, London, UK Aetiology

More information

Update on bronchiectasis guidelines. James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK

Update on bronchiectasis guidelines. James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK Update on bronchiectasis guidelines James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK University of Dundee Bronchiectasis guidelines 2017 2010 2006 2008 2015 2015 Currently valid guidelines

More information

COPD Treatable. Preventable.

COPD Treatable. Preventable. My COPD Action Plan Patient s Copy (Patient s Name) Date Canadian Respiratory COPD Treatable. Preventable. This is to tell me how I will take care of myself when I have a COPD flare-up. My goals are My

More information

CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions

CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions Issue 1: Hypertonic Saline Summary: Preserving lung function is a crucial element in the care of the individual with

More information

Sandra Gursli 1, Leiv Sandvik 2, Egil Bakkeheim 1, Bjørn Skrede 3 and Britt Stuge 4. Introduction. Original Article

Sandra Gursli 1, Leiv Sandvik 2, Egil Bakkeheim 1, Bjørn Skrede 3 and Britt Stuge 4. Introduction. Original Article 697505SMO0010.1177/2050312117697505SAGE Open MedicineGursli et al. research-article2017 Original Article SAGE Open Medicine Evaluation of a novel technique in airway clearance therapy Specific Cough Technique

More information

Master of Physical Therapy Program: Year 2 CARDIORESPIRATORY COURSE OUTLINES SUMMARY

Master of Physical Therapy Program: Year 2 CARDIORESPIRATORY COURSE OUTLINES SUMMARY Master of Physical Therapy Program: Year 2 CARDIORESPIRATORY COURSE OUTLINES SUMMARY Course: PT 6124 Physical Therapy and Hospital based Care Through lecture, tutorial and laboratory sessions, students

More information

Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life?

Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life? Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life? Summary of the evidence located: According to the NICE guideline on Chronic Obstructive Pulmonary Disease

More information

Where Therapy is Moving Monarch Airway Clearance System

Where Therapy is Moving Monarch Airway Clearance System Where Therapy is Moving Monarch Airway Clearance System Mobile therapy that works. 1,2,3 The Monarch Airway Clearance System is a high frequency chest wall oscillation (HFCWO) therapeutic device with revolutionary

More information

What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF

What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic

More information

Bronchiectasis in Adults - Suspected

Bronchiectasis in Adults - Suspected Bronchiectasis in Adults - Suspected Clinical symptoms which may indicate bronchiectasis for patients Take full respiratory history including presenting symptoms, past medical & family history Factors

More information

Understanding COPD (UCOPD) Questionnaire. User Manual

Understanding COPD (UCOPD) Questionnaire. User Manual Understanding COPD (UCOPD) Questionnaire User Manual [Version 1.0 - Date: 12.01.2012] Dr Brenda O Neill 1 Dr Denise Cosgrove 1 Dr Joseph MacMahon 2 Dr Judy Bradley 1,2 1 Health and Rehabilitation Sciences

More information

Where Therapy is Moving Monarch Airway Clearance System

Where Therapy is Moving Monarch Airway Clearance System Where Therapy is Moving Monarch Airway Clearance System Mobile therapy that works. 1,2,3 The Monarch Airway Clearance System is a high frequency chest wall oscillation (HFCWO) therapeutic device with revolutionary

More information

Bronchiectasis. Examples include: Viral infections (measles, adenovirus, influenza)

Bronchiectasis. Examples include: Viral infections (measles, adenovirus, influenza) Bronchiectasis What is Bronchiectasis? Bronchiectasis (pronounced bron-kee-ek'-tas-is) is a condition of the airways in the lungs. These airways (bronchial tubes) are tubelike structures that branch from

More information

Cough Assist. Information for patients, families and carers Therapy Services

Cough Assist. Information for patients, families and carers Therapy Services Cough Assist Information for patients, families and carers Therapy Services PROUD TO MAKE A DIFFERENCE SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST page 2 of 16 Table of contents Why do I need a Cough

More information

Bronchiectasis exacerbations; differences and management. Michael Loebinger Royal Brompton Imperial College

Bronchiectasis exacerbations; differences and management. Michael Loebinger Royal Brompton Imperial College Bronchiectasis exacerbations; differences and management Michael Loebinger Royal Brompton Imperial College Plan Bronchiectasis background and burden Exacerbation and Management Longer term Management Cases

More information

THE WINSTON CHURCHILL MEMORIAL TRUST OF AUSTRALIA. Report by Jamie Wood BSc. (Physiotherapy) Churchill Fellow

THE WINSTON CHURCHILL MEMORIAL TRUST OF AUSTRALIA. Report by Jamie Wood BSc. (Physiotherapy) Churchill Fellow THE WINSTON CHURCHILL MEMORIAL TRUST OF AUSTRALIA Report by Jamie Wood BSc. (Physiotherapy) 2004 2010 Churchill Fellow To study physiotherapy service and techniques for people with cystic fibrosis and

More information

Where Therapy is Moving Monarch Airway Clearance System

Where Therapy is Moving Monarch Airway Clearance System Where Therapy is Moving Monarch Airway Clearance System Mobile therapy that works. 1,2,3 The Monarch Airway Clearance System is a high frequency chest wall oscillation (HFCWO) therapeutic device with revolutionary

More information

High Frequency Chest Wall Oscillating Devices (HFCWO) (Airway Clearance Systems)

High Frequency Chest Wall Oscillating Devices (HFCWO) (Airway Clearance Systems) High Frequency Chest Wall Oscillating Devices (HFCWO) (Airway Clearance Systems) Date of Origin: 05/2015 Last Review Date: 07/26/2017 Effective Date: 07/26/2017 Dates Reviewed: 07/2016 Developed By: Medical

More information

MND Study Day. Martin Latham CNS Leeds Sleep Service

MND Study Day. Martin Latham CNS Leeds Sleep Service MND Study Day Martin Latham CNS Leeds Sleep Service Objectives: Identifying individuals at risk. Understand issues related to NIV. Understand issues related to secretion management Improve outcomes. Identifying

More information

Up to 50% of continuous flow oxygen therapy patients experience clinically significant nocturnal desaturation. 1

Up to 50% of continuous flow oxygen therapy patients experience clinically significant nocturnal desaturation. 1 Up to 50% of continuous flow oxygen therapy patients experience clinically significant nocturnal desaturation. 1 Continuous Flow Oxygen Delivery & Sleep A number of theories and studies are published surrounding

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Citation for published version (APA): Schans, C. P. V. D. (1991). Physiotherapy and bronchial mucus transport s.n.

Citation for published version (APA): Schans, C. P. V. D. (1991). Physiotherapy and bronchial mucus transport s.n. University of Groningen Physiotherapy and bronchial mucus transport van der Schans, Cees P. IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from

More information

Pulmo Waves Device for respiratory physiotherapy

Pulmo Waves Device for respiratory physiotherapy MADE IN ITALY Pulmo Waves Device for respiratory physiotherapy Respiratory physiotherapy Accumulation of secretions in certain parts of the human respiratory system can take place for different reasons.

More information

The Most Effective Form of Airway Clearance Therapy to Preserve the Pulmonary Function in Cystic Fibrosis Patients

The Most Effective Form of Airway Clearance Therapy to Preserve the Pulmonary Function in Cystic Fibrosis Patients Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects 8-15-2009 The Most Effective Form of Airway Clearance Therapy to Preserve the Pulmonary

More information

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam

More information